Adnexal Masses in Menopausal Women
|
|
- Patricia Watkins
- 6 years ago
- Views:
Transcription
1 Adnexal Masses in Menopausal Women Surgery or Surveillance? Disclosure Frederick R. Ueland, MD Professor and Director Division of Gynecologic Oncology University of Kentucky I have no financial disclosures Ovarian Tumor Overview Wind River Range, WY July, 2017 Past 1980 s palpable ovary syndrome 2000 s observation of unilocular cysts 2010 s observation of septate cysts Present 10% require surgery for adnexal mass in their lifetime 1 13%-21% are malignant 2 1) Moore, McMeekin, Brown et al. Gynecol Oncol, ) Jordan. Current Biomarker Findings,
2 Ovarian Tumor Overview The Specifics Premenopausal Many tumors, few cancers 15% are malignant - Germ cell tumors - LMP tumors - Epithelial cancers Benign tumors - 70% functional cysts - 20% neoplastic - 10% endometriomas Other - Inflammatory Menopausal Few tumors, many cancers 50% are malignant - Epithelial ovarian cancer - Metastatic cancer - Granulosa cell tumors Benign tumors - Cystadenoma - Fibroma - Thecoma 39,337 ultrasounds performed 30% high risk (9%) solid cyst+solid unilocular 70% 30% septate Normal Abnormal 70% low risk (21%) Pavlik E, Ueland F, Miller R, et al. Obstet Gynecol, 2013 Menopausal Women Incidence Number of new ovarian cysts identified 8.2% million women 2 Prevalence Proportion who have cysts at any given time 17% million women 2 Most are low risk for malignancy Ultrasound Lessons Learned Reducing Subjectivity IOTA: Simple Rules, ADNEX Model Kentucky Morphology Index 1) Pavlik E, Ueland F, Miller, R. et al. Obstet Gynecol, ) United States Census Bureau,
3 Lessons Learned Limiting Subjectivity Tumor morphology helps stratify cancer risk Screening trial Surgeries per cancer - UKCTOCS PLCO Kentucky first decade (1990 S) 12.5 second decade (2000 S) 5.2 third decade (2010 S) 4.0 First International Consensus Report 1 International Ovarian Tumor Analysis (IOTA) o Simple Rules 2 o ADNEX 3 Kentucky Morphology index 4 Serial sonography 5 9 1) J Ultrasound Med, 2017; 2) Ultrasound Obstet Gynecol, 2008; 3) Br Med J, 2014; 4) Gynecol Oncol, 2003; 5) Gynecol Oncol, 2014 IOTA Simple Rules M1 Irregular solid M2 Presence of ascites M3 At least 4 papillary projections M4 Irregular multilocular solid, largest diameter 10 cm M5 Very strong blood flow B1 Unilocular B2 Solid component < 7 mm B3 Presence of acoustic shadows B4 Smooth multilocular tumor, largest diameter < 10 cm B5 No blood flow Timmerman et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 31; ,
4 Simple Rules Malignant If one or more M-rules apply in the absence of a B-rule, the mass is classified as malignant Benign If one or more B-rules apply in the absence of an M-rule, the mass is classified as benign. Indeterminate If both M-rules and B-rules apply, the mass cannot be classified. If no rule applies, the mass cannot be classified Timmerman et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 31; , 2008 ADNEX Risk Model Belgium, Italy, Czech Republic, Poland, UK, Sweden IOTA - ADNEX model 1. Age of the patient at examination (years) 2. Oncology center (referral center for gyn-oncol)? 3. Maximal diameter of the lesion (mm) 4. Maximal diameter of the largest solid part (mm) 5. More than 10 locules? 6. Number of papillations (papillary projections) 7. Acoustic shadows present? 8. Ascites (fluid outside pelvis) present? 9. Serum CA-125 (U/ml) Clear Van Calster et al. Evaluating risk of ovarian cancer before surgery using the ADNEX 14model. BMJ, 2014 Kentucky Morphology Index Kentucky MI Ueland F, DePriest P, Pavlik E, et al. Gynecol Oncol, 2003 MI Total Malignant ROM (%) 1 2, , , , , % Total 10, Ueland F, DePriest P, Pavlik E, et al. Gynecol Oncol, 2003 Sensitivity 86% Specificity 98% 4
5 Comparing Models ADNEX Model ROM correlates with increased cancer risk 52% of cancers in lowest ROM groups Efficacy in surveillance is unknown Misses stage 1 cancers Kentucky MI ROM correlates with increased cancer risk 15% of cancers in lowest ROM groups MI change over time is useful for surveillance Identifies stage 1 cancers Biomarkers Diagnostic Triage Comparison Lefringhouse J, Ueland F, Ore R, et al. SGO, Diagnostic Biomarkers CEA CA19 9 LDH β hcg AFP HE 4 CA125 Triage Biomarkers OVA1 * ROMA Overa + CA125 Performance * Multivariate Index Assay + MIA2G 19 Myers et al. Management of adnexal mass. Rockville (MD): U.S. Department of Health and Human Services,
6 OVA1 Triage Biomarker Tests FDA-cleared September, 2009 Multivariate Index Assay Range 0-10 Premenopausal Post Low Risk < 5.0 < 4.4 High Risk ROMA FDA-cleared September, 2011 Dual marker test Range 0-10 Premenopausal Post Low Risk < 1.31 < 2.77 High Risk CA125 + HE4 Triage Biomarker Tests Overa FDA-cleared September, 2016 Multivariate Index Assay-2G CA125, HE-4, FSH, Apolipoprotein A1, Transferrin Range 0-10 Result Low Risk < 5.0 High Risk Comparing Biomarkers Sensitivity Overa 1 OVA1 2,3 ROMA 4 CA125 II 2,5 All malignancies 91% 93% 89% 69% Epithelial ovarian cancers 95% 99% 94% 82% Early stage EOC 89% 98% 75% 66% Premenopausal women 90% 94% 76% 36% Postmenopausal women 92% 100% 92% 80% Specificity All malignancies 69% 54% 75% 87% Recommended Evaluation Determine Malignant Risk with Ultrasound 1. Low risk surveillance 2. Indeterminate secondary testing 3. High risk refer to Gynecologic Oncologist OVA1 detected 76% of malignancies missed by CA ) Coleman R, Herzog T, Chan D, et al. Am J Obstet Gynecol, ) Ueland F, DeSimone C, Seamon L, et al. Obstet Gynecol, ) Bristow R, Smith A, Zhang Z, et al. Gynecol Oncol, ) Moore R, McMeekin S, Brown A, et al. Gynecol Oncol, ) Myers et al. Management of adnexal mass. Rockville (MD): U.S. Department of HHS,
7 Recommended Evaluation Low Risk Malignant Risk Low Indeterminate High Distribution 65% 25% 10% US morphology Secondary testing Unilocular or septate Partly solid, small wall abnormalities Mostly solid, papillary projections No YES No Surgery No Maybe YES Smooth-walled Unilocular or septate Unilocular cyst 1,2 Septate cyst3 25 1) Modesitt et al. Gynecol Oncol, 2003; 2) Bailey et al. Gynecol Oncol, 1998; 3) Saunders B. et al. Gynecol Oncol, 2010 Malignant Potential for Low Risk Resolution for Low Risk Resolution Time Type of Abnormality Cyst Cyst & Septae Cyst & Solid Solid Summary of Valentin et al, % unilocular 1% malignant 0.54% Premenopausal 2.76% Postmenopausal 7/11 had solid or papillary component on visual surgical inspection Valentin, Ameye, Franchi et al. Ultrasound Obstet Gynecol, Scans 6, Abnormalities 1, Average Scans Mean (mo) Median (mo) th percentile (mo) th percentile (mo) Ore R, Ueland F, Lefringhouse J, et al. SGO Annual Meeting abstract,
8 Recommended Evaluation Malignant Risk Low Indeterminate High Distribution 65% 25% 10% Indeterminate Risk Small, irregular wall abnormalities Partly solid Atypical, non-papillary projections US morphology Secondary testing Unilocular or septate Partly solid, small wall abnormalities Mostly solid, papillary projections No YES No Surgery No Maybe YES Serial Morphology Index Tumor type MI score Malignant Increase Non malignant Stable or gradual rise Resolving Decrease Elder J, Pavlik E, Long A et al. Gynecol Oncol 135; 8-12, Surgery for epithelial ovarian malignancy * 24 subjects had 1 scan only N MI P-value MI per month P-value 50 * 1.9 P< P<0.001 Surgery for non-malignancy P< P<0.001 Resolved ovarian cysts P< P<
9 Recommended Evaluation High Risk Malignant Risk Low Indeterminate High Distribution 65% 25% 10% US morphology Secondary testing Unilocular or septate Partly solid, small wall abnormalities Mostly solid, papillary projections No YES No Surgery No Maybe YES Irregular, solid Papillations Ascites ROM >25% Refer to Gyn Oncologist Summary Questions? 1. Ultrasound is the preferred test to evaluate an ovarian tumor 2. Risk of malignancy Low- monitor without surgery 6 months, then annually for 5 years Indeterminate- secondary testing Serial ultrasound Biomarker testing (OVA1, ROMA, Overa) High- surgery Refer to a Gynecologic Oncologist 35 9
Adnexal Masses in Menopausal Women Surgery or Surveillance?
Adnexal Masses in Menopausal Women Surgery or Surveillance? FREDTALK IDEASWORTHSPREADING Disclosure I am a member of Vermillion s Speakers Bureau I am NOT a paid consultant for Vermillion Inc. nor do I
More informationOVARIAN MASSES : MANAGEMENT CHALLENGE
SRU 2015 OVARIAN MASSES : MANAGEMENT CHALLENGE phyllis.glanc@sunnybrook.ca Sunnybrook Health Science Centre University of Toronto, Dept Medical Imaging, Obstetrics & Gynecology Thank you on behalf of the
More informationISUOG Basic Training Typical Ultrasound Appearances of Common Pathologies in the Adnexae
ISUOG Basic Training Typical Ultrasound Appearances of Common Pathologies in the Adnexae Learning objectives At the end of the lecture series you will be able to: Compare the differences between typical
More informationClinical, ultrasound parameters and tumor marker-based mathematical models and scoring systems in pre-surgical diagnosis of adnexal tumors
REVIEW / GYNECOLOGY Ginekologia Polska 2016, vol. 87, no. 12, 824829 Copyright 2016 Via Medica ISSN 00170011 DOI: 10.5603/GP.2016.0096 Clinical, ultrasound parameters and tumor marker-based mathematical
More informationThe key contribution of MRI in adnexal mass evaluation is in: 1. Identifying benign features. 2. Identifying malignant features.
19 th Annual Women s Imaging Conference University of Toronto - 2016 Disclosures : None phyllis.glanc@sunnybrook.ca Sunnybrook Health Science Centre University of Toronto, Dept Medical Imaging, Obstetrics
More informationDiagnostics guidance Published: 15 November 2017 nice.org.uk/guidance/dg31
Tests in secondary care to identify people at high risk of ovarian cancer Diagnostics guidance Published: 15 November 2017 nice.org.uk/guidance/dg31 NICE 2017. All rights reserved. Subject to Notice of
More informationSCREENING FOR OVARIAN CANCER DR MACİT ARVAS
SCREENING FOR OVARIAN CANCER DR MACİT ARVAS Ovarian cancer is the leading cause of death from gynecologic malignancy In 2008, ovarian cancer was the seventh common cancer in women worldwide There were
More informationCAN TV U/S REDUCE THE
CAN TV U/S REDUCE THE NEED FOR SURGERY IN GYNECOLOGY? Steven R. Goldstein, M.D. Professor of Obstetrics & Gynecology New York University it School of fmedicine i Director of Gynecologic Ultrasound Co-Director
More informationTriage of Ovarian Masses. Andreas Obermair Brisbane
Triage of Ovarian Masses Andreas Obermair Brisbane Why Triage? In ovarian cancer, best outcomes for patients can be achieved when patients are treated in tertiary centres by a multidisciplinary team led
More informationTitle of Guideline (must include the word Guideline not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline not protocol, policy, procedure etc) Author: Contact Name and Job Title Directorate & Speciality Assessment, referral and initial management of ultrasound
More informationIOTA and Models for Screening for Ovarian Cancer
IOTA and Models for Screening for Ovarian Cancer Hennie Botha MARCH 2017 T H IG PY R O C F O SP EA KE R Silent Killer to Whispering Disease Listening to your body.. new, persistent, and increases in severity
More informationAdnexal Mass Management: Risk Stratification and Management Practice for Best Patient Outcomes
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Author: Contact Name and Job Title Directorate & Speciality Assessment, referral and initial management of ultrasound
More informationThe International Ovarian Tumour Analysis (IOTA) criteria
The International Ovarian Tumour Analysis (IOTA) criteria Elizabeth Bullivant Specialist Sonographer Sheffield Teaching Hospitals NHS Foundation Trust Contents Ultrasound reports. What is IOTA? What the
More informationTerminology Estimate the risk of malignancy in adnexal masses - Overview
Understanding the IOTA (International Ovarian Tumor Analysis) terminology & Classification Using the IOTA simple rules to estimate the risk of malignancy in women with adnexal masses Elisabeth Epstein,
More informationThe Adnexal Mass. Handout NCUS 3/18/2017 Suzanne Dixon, MD
The Adnexal Mass Handout NCUS 3/18/2017 Suzanne Dixon, MD Objectives: Pelvic mass differential Characteristics of the normal ovary Standard terminology for ovarian masses Benign vs. malignant features
More information2/24/19. Ovarian pathology: IOTA ADNEXAL MASSES. Content. IOTA terms for description of an adnexal mass. IOTA terms for description of an adnexal mass
Content Ovarian pathology: IOTA ADNEXAL MASSES X SIMPLE COMPLEX Dr DESCRIBE WHAT YOU SEE FRANZCOG, MPH, DDU, COGU Sonologist Clinically useful Benign Malignant Communication between clinicians/research
More informationPublic Statement: Medical Policy Statement: Limits: Medical Policy Title: OVA1, Detection of Ovarian Cancer. ARBenefits Approval: 10/26/2011
ARBenefits Approval: 10/26/2011 Effective Date: 01/01/2012 Revision Date: 08/21/2013 Medical Policy Title: OVA1, Detection of Ovarian Cancer Document: ARB0295:02 Administered by: Public Statement: The
More informationGynaecological cancers. Mr Vivek Nama MD MRCOG Consultant Gynaecological Oncologist
Gynaecological cancers Mr Vivek Nama MD MRCOG Consultant Gynaecological Oncologist Gynaecological cancers Why do we need 2 week wait? Early/timely diagnosis of cancer Possibly less invasive treatment and
More informationCA125 in the diagnosis of ovarian cancer: the art in medicine
CA125 in the diagnosis of ovarian cancer: the art in medicine Dr Marcia Hall Consultant Medical Oncology Mount Vernon Cancer Centre Hillingdon Hospital Wexham Park Hospital Epidemiology Ovarian cancer
More informationA new scoring model for characterization of adnexal masses based on two-dimensional gray-scale and colour Doppler sonographic features
FVV in ObGyn, 2014, 6 (2): 68-74 Original paper A new scoring model for characterization of adnexal masses based on two-dimensional gray-scale and colour Doppler sonographic features Ahmed M. Abbas, Kamal
More informationAn international multidisciplinary panel of experts was convened
SPECIAL COMMUNICATION First International Consensus Report on Adnexal Masses Management Recommendations Phyllis Glanc, MD, Beryl Benacerraf, MD, Tom Bourne, MD, PhD, Douglas Brown, MD, Beverly G. Coleman,
More informationOvarian Lesion Benign vs Malignant?
Ovarian Lesion Benign vs Malignant? Michele Keenan 1,2 Bernice Dunne 2 Mary Moran 1 Therese Herlihy 1 1. Radiography and Diagnostic Imaging, School of Medicine, University College Dublin, Ireland 2. Midland
More informationGynecologic Ultrasound. Sujata Ghate, MD Associate Professor of Radiology Duke University Medical Center
Gynecologic Ultrasound Sujata Ghate, MD Associate Professor of Radiology Duke University Medical Center Objectives Understand work-up of endometrial abnormalities Show examples of uterine and endometrial
More informationVERMILLION Multi-Modal BioInformatics Solution for Ovarian Cancer
VERMILLION Multi-Modal BioInformatics Solution for Ovarian Cancer NASDAQ: VRML l August 2018 2018 Vermillion Inc. All Rights Reserved 1 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking
More informationMinimally Invasive Gynecologic Surgery: Laparoscopic Treatment of the Pelvic Mass
Minimally Invasive Gynecologic Surgery: Laparoscopic Treatment of the Pelvic Mass R. Wendel Naumann, M.D. Director, Minimally Invasive Surgery in Gyn Oncology Carolinas Medical Center Charlotte, NC wnaumann@mac.com
More informationStage IA Ovarian Cancers
ORIGINL RESERCH Stage I Ovarian Cancers Comparison of Sonographic Findings and Histopathologic Types etween Patients With Normal and Elevated Serum Cancer ntigen 125 Levels Makiko Hirai, MD, Yasuo Hirai,
More informationIs It Time To Implement Ovarian Cancer Screening?
Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya
More informationDiane DeFriend Derriford Hospital, Plymouth
Diane DeFriend Derriford Hospital, Plymouth Ultrasound US remains primary imaging modality for investigation of an adnexal mass Aim to characterise Benign Malignant Indeterminate 90% adnexal masses characterised
More informationTop Tips for Gynaecological Ultrasound. Catherine Kirkpatrick Consultant Sonographer Dublin Oct 2018
Top Tips for Gynaecological Ultrasound Catherine Kirkpatrick Consultant Sonographer Dublin Oct 2018 We can all scan a pelvis so what can we do to improve? Uterus, endometrium and ovaries, got it covered!
More informationProtocol. Multimarker Serum Testing Related to Ovarian Cancer
Protocol Multimarker Serum Testing Related to Ovarian Cancer (20462) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 01/11, 01/12, 01/13, 01/14, 01/15,
More informationMulti-Modal BioInformatics Solution for Ovarian Cancer
VERMILLION Multi-Modal BioInformatics Solution for Ovarian Cancer NASDAQ: VRML l April 2019 2019 Vermillion Inc. All Rights Reserved 1 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking
More informationThe natural history of adnexal cysts incidentally detected at. transvaginal ultrasound examination in postmenopausal women
Ultrasound Obstet Gynecol 2002; 20: 174 180 The natural history of adnexal cysts incidentally detected at Blackwell Science, Ltd transvaginal ultrasound examination in postmenopausal women L. VALENTIN*
More informationThis policy is applicable to Commercial Products only. For BlueCHiP for Medicare, see Related Policy section.
Medical Coverage Policy Multimarker Serum Testing Related to Ovarian Cancer EFFECTIVE DATE: 10 01 2015 POLICY LAST UPDATED: 04 17 2018 OVERVIEW This policy documents the coverage determination for Multimarker
More informationMULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER
MULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationAssessment of adnexal masses. Ultrasound workup of adnexal masses. symptoms. symptoms. Age. Serum tumor markers 10/1/2018
Assessment of adnexal masses Ultrasound workup of adnexal masses Kevin Robinson, DO Department of Radiology Michigan State University October 4, 2018 Patients symptoms Age Menstrual status Serum tumor
More informationUbol Saeng-Anan, Tawiwan Pantasri, Vithida Neeyalavira, Theera Tongsong*
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.9.5409 RESEARCH ARTICLE Sonographic Pattern Recognition of Endometriomas Mimicking Ovarian Cancer Ubol Saeng-Anan, Tawiwan Pantasri, Vithida Neeyalavira, Theera
More informationGynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer
Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy
More informationAccepted Manuscript. Ultrasound and adnexal pathology: what is the evidence? Wouter Froyman, MD, Lil Valentin, MD, PhD, Dirk Timmerman, MD, PhD
Accepted Manuscript Ultrasound and adnexal pathology: what is the evidence? Wouter Froyman, MD, Lil Valentin, MD, PhD, Dirk Timmerman, MD, PhD PII: S0002-9378(16)30461-6 DOI: 10.1016/j.ajog.2016.07.027
More informationUnexpected Gynecologic Findings at Laparotomy. Susan A. Davidson, MD University of Colorado, Denver School of Medicine
Unexpected Gynecologic Findings at Laparotomy Susan A. Davidson, MD University of Colorado, Denver School of Medicine Adnexal Mass: Gyn Etiologies Uterine Leiomyomas Pregnancy Malignancy Tubal Pregnancy
More informationRESEARCH ARTICLE. Hariyono Winarto*, Bismarck Joel Laihad, Laila Nuranna. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.5.1949 RESEARCH ARTICLE Modification of Cutoff Values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for Ovarian Cancer Detection
More informationREVIEW ARTICLE ABSTRACT
10.5005/jp-journals-10009-1273 Jesús Utrilla-Layna et al REVIEW ARTICLE Predicting Malignancy in Entirely Solid-appearing Adnexal Masses on Gray-Scale Ultrasound Based on Additional Ultrasound Findings,
More informationAmerican Journal of Obstetrics and Gynecology
Accepted Manuscript Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis (IOTA) group Dirk Timmerman, MD, PhD, Ben Van Calster, MSc,
More informationThe role of ultrasound in detecting early ovarian carcinoma:the National Ovarian Cancer Early Detection Program
The role of ultrasound in detecting early ovarian carcinoma:the National Ovarian Cancer Early Detection Program D.A. Fishman 1,2,3 L. Cohen 1,3, K. Bozorgi 1,2,3 R.Tamura 1,3 and J.R. Lurain 1,3 Ovarian
More informationCorporate Medical Policy
Corporate Medical Policy Proteomics-based Testing Related to Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomics_based_testing_related_to_ovarian_cancer 7/2010
More informationFew cysts present with sudden pain OBG. Hallmarks of a benign cyst Page 58. Hemorrhagic cyst at detection and 2 weeks later Page 61 IN THIS ARTICLE
OBG MANAGEMENT William H. Parker, MD Chair, Obstetrics and Gynecology Saint John's Health Center Santa Monica, Calif Clinical Professor of Obstetrics and Gynecology UCLA School of Medicine Los Angeles
More informationUltrasound characteristics of different types of adnexal malignancies.
Ultrasound characteristics of different types of adnexal malignancies. Valentin, Lil; Ameye, Lieveke; Testa, Antonia; Lécuru, Fabrice; Bernard, Jean-Pierre; Paladini, Dario; Van Huffel, Sabine; Timmerman,
More informationبسم هللا الرحمن الرحيم. Prof soha Talaat
بسم هللا الرحمن الرحيم Ovarian tumors The leading indication for gynecologic surgery. Preoperative characterization of complex solid and cystic adnexal masses is crucial for informing patients about possible
More informationFrequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation
Ultrasound Obstet Gynecol 2003; 22: 284 289 Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.212 Frequency and type of adnexal lesions in autopsy material from postmenopausal
More informationOVARIAN CARCINOMA Immune Therapy. Antibodies to CA-125 (Ovarex) Vaccine therapy
OVARIAN CARCINOMA Immune Therapy Antibodies to CA-125 (Ovarex) Vaccine therapy OVARIAN CARCINOMA Targeted Therapy Bevacizumab (Avastin): GOG- 218 Anti-VEGF, angiogenesis inhibitor TLK 286 (Telcyta): Glutathione
More informationSimple ultrasound-based rules for the diagnosis of ovarian cancer
Ultrasound Obstet Gynecol 2008; 31: 681 690 Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.5365 Simple ultrasound-based rules for the diagnosis of ovarian cancer
More informationTable E2. Studies from 1998 November 2008 That Focus on Performance of Imaging Modalities for Ovarian Lesion Detection and Characterization
Table E2. Studies from 1998 November 2008 That Focus on Imaging Modalities for Ovarian Lesion Detection and Characterization No. of No. of Tumor Types and Sensitivity Specificity PPV NPV Accuracy False-Positive
More informationJoshua Cohen MD Gynecologic Oncology Fellow UCLA/Cedars-Sinai Medical Center
Joshua Cohen MD Gynecologic Oncology Fellow UCLA/Cedars-Sinai Medical Center No conflicts of interest to disclose Educational Objectives Recognize challenges in current paradigms associated with biomarker
More informationHuman epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts
Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts Ovarian cancer is diagnosed annually in more than 200,000 women worldwide, with
More informationDiagnostic Bioinformatic Solutions to Change Gynecologic Outcomes
Diagnostic Bioinformatic Solutions to Change Gynecologic Outcomes NASDAQ: VRML JANUARY 2017 1 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, as defined in the Private
More informationM. J. KUDLA* and J. L. ALCÁZAR ABSTRACT
Ultrasound Obstet Gynecol 2010; 35: 602 608 Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.7601 Does sphere volume affect the performance of three-dimensional power
More informationDiagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses
Ultrasound Obstet Gynecol 9;:277 2 Diagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses S. Guerriero, S. Ajossa, A. Risalvato, M. P. Lai, V.
More informationThe Role of Imaging for Gynecologic Emergencies
Objectives The Role of Imaging for Gynecologic Emergencies M. Jonathon Solnik, MD, FACOG FACS Associate Professor of Obstetrics & Gynaecology Head of Gynaecology & Minimally Invasive Surgery University
More informationBecause ovarian cancer is usually diagnosed
OVARIAN CANCER Recent studies shed light on early detection of but it s not a green light for routine screening. Until promising avenues of research lead further, refer women who have an adnexal mass,
More informationRisk of Malignancy Index in the Preoperative Evaluation of Patients with Adnexal Masses among Women of Perimenopausal and Postmenopausal Age Group
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 9 Ver. 8 (September. 2018), PP 20-25 www.iosrjournals.org Risk of Malignancy Index in the Preoperative
More informationRESEARCH. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group Dirk Timmerman, professor in obstetrics and gynaecology, 1 Lieveke
More informationMultimodal approach to predict ovarian malignancy prior to laparoscopy
2017; 3(2): 149-153 ISSN Print: 2394-7500 ISSN Online: 2394-5869 Impact Factor: 5.2 IJAR 2017; 3(2): 149-153 www.allresearchjournal.com Received: 24-12-2016 Accepted: 25-01-2017 Dr. Juhi Bhatti Dr. Shriraj
More informationPathology of Ovarian Tumours. Dr. Jyothi Ranganathan MD ( Path) AFMC Pune PDCC (Cytopathology) PGI Chandigarh
Pathology of Ovarian Tumours Dr. Jyothi Ranganathan MD ( Path) AFMC Pune PDCC (Cytopathology) PGI Chandigarh Outline Incidence Risk factors Classification Pathology of tumours Tumour markers Prevention
More informationGynaecology: Diagnosis and management of ovarian and / or adnexal masses. 1, Introduction and who the guideline applies to:
Gynaecology: Diagnosis and management of ovarian and / or adnexal masses 1, Introduction and who the guideline applies to: This guideline is aimed at clinicians in primary and secondary care looking after
More informationAUGUST Vermillion Inc. All Rights Reserved
z AUGUST 2017 2017 Vermillion Inc. All Rights Reserved Forward Looking Statements This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995.
More informationORIGINAL CONTRIBUTIONS
477 Indian Journal of Medical Sciences (INCORPORATING THE MEDICAL BULLETIN) VOLUME 62 DECEMBER 2008 NUMBER 12 ORIGINAL CONTRIBUTIONS OVARIAN CRESCENT SIGN AND SONOMORPHOLOGICAL INDICES IN PREOPERATIVE
More informationProteomics-Based Testing for the Evaluation of Ovarian (Adnexal) Masses
Proteomics-Based Testing for the Evaluation of Ovarian (Adnexal) Masses Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationMultimarker Serum Testing Related to Ovarian Cancer
Multimarker Serum Testing Related to Ovarian Cancer Policy Number: 2.04.62 Last Review: 2/2018 Origination: 9/2010 Next Review: 9/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not
More informationReliability of preoperative evaluation of postmenopausal ovarian tumors
Niemi et al. Journal of Ovarian Research (2017) 10:15 DOI 10.1186/s13048-017-0309-4 RESEARCH Reliability of preoperative evaluation of postmenopausal ovarian tumors Open Access Riikka Johanna Niemi 1*,
More informationMultimarker and Proteomics-based Serum Testing Related to Ovarian Cancer
Medical Policy Manual Laboratory, Policy No. 60 Multimarker and Proteomics-based Serum Testing Related to Ovarian Cancer Next Review: December 2018 Last Review: January 2018 Effective: February 1, 2018
More informationINCIDENTAL FINDINGS IN GYN ULTRASOUND:WHAT DO YOU DO?
INCIDENTAL FINDINGS IN GYN ULTRASOUND:WHAT DO YOU DO? Steven R. Goldstein, M.D. Professor of Obstetrics & Gynecology New York University School of Medicine Director of Gynecologic Ultrasound Co-Director
More informationP. SLADKEVICIUS and L. VALENTIN ABSTRACT
Ultrasound Obstet Gynecol 2013; 41: 318 327 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.12289 Intra- and interobserver agreement when describing adnexal masses using
More informationAssessment of benefit of ultrasound monitoring of adnexal masses <10 cm on ovarian cancer early detection
Assessment of benefit of ultrasound monitoring of adnexal masses
More informationEvaluation of the Ovarian Crescent Sign in the Preoperative Determination of the Nature of Adnexal Masses
OVARIAN THE IRAQI POSTGRADUATE CRESCENT SIGN MEDICAL IN ADNEXAL JOURNAL MASSES Evaluation of the Ovarian Crescent Sign in the Preoperative Determination of the Nature of Adnexal Masses Neda Salih Amen*,
More informationPhD Summary. J. Kaijser 1,2 Promotor:T. Bourne 1,2,3 Co-promotors: B. Van Calster 1, D. Timmerman 1,2. Abstract
Facts Views Vis Obgyn, 2015, 7 (1): 42-59 PhD Summary Towards an evidence-based approach for diagnosis and management of adnexal masses: findings of the International Ovarian Tumour Analysis (IOTA) studies
More informationPreoperative diagnosis of metastatic ovarian cancer is related to origin of primary tumor
Ultrasound Obstet Gynecol 2012; 39: 581 586 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.10120 Preoperative diagnosis of metastatic ovarian cancer is related to origin
More informationThe National Institutes of Health released a consensus
Performance of the American College of Obstetricians and Gynecologists Ovarian Tumor Referral Guidelines With a Multivariate Index Assay Rachel Ware Miller, MD, Alan Smith, MS, Christopher P. DeSimone,
More informationPractical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors
Facts Views Vis Obgyn, 2015, 7 (1): 32-41 Review Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors B. Van Calster 1,*, K.
More informationHE4 Human Epididymal Protein 4 A novel oncological biomarker improving ovarian cancer care
HE4 Human Epididymal Protein 4 A novel oncological biomarker improving ovarian cancer care Ovarian cancer Worldwide, ovarian cancer is the second leading cancer in women and the fourth common cause of
More informationOvarian simple cysts in asymptomatic postmenopausal women detected at transvaginal ultrasound: A review of literature
W J O G World Journal of Obstetrics and Gynecology Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5317/wjog.v4.i4.108 World J Obstet Gynecol
More informationVERMILLION. Diagnostic Bioinformatic Solutions to Change Gynecologic Outcomes. NASDAQ: VRML NOVEMBER Vermillion Inc. All Rights Reserved
VERMILLION Diagnostic Bioinformatic Solutions to Change Gynecologic Outcomes NASDAQ: VRML NOVEMBER 2017 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, as defined in the
More informationONCOLOGY LETTERS 12: , 2016
ONCOLOGY LETTERS 12: 3101-3114, 2016 Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay
More informationA NEW QUANTITATIVE METHOD TO EVALUATE ADNEXAL TUMORS
ORIGINAL ARTICLE A NEW QUANTITATIVE METHOD TO EVALUATE ADNEXAL TUMORS Chung-Yuan Lee, Ching-Cheng Tseng, Chen-Bin Wang, Yu-Hsiang Lin, Chun-Hung Chen, Ting-Hung Wun, Ying-Lun Sun, Chih-Jen Tseng* Department
More informationA Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come
University of Kentucky UKnowledge Obstetrics Gynecology Faculty Publications Obstetrics Gynecology 3-8-2017 A Perspective on Ovarian Cancer Biomarkers: Past, Present Yet-To-Come Frederick R. Uel University
More information3 Summary of clinical applications and limitations of measurements
CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin-16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant
More informationProspective evaluation of three different models for the pre-operative diagnosis of ovarian cancer
British Journal of Obstetrics and Gynaecology November 2000, Vol107, pp. 1347-1353 Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer *N. Aslam Research
More informationACR Appropriateness Criteria Clinically Suspected Adnexal Mass EVIDENCE TABLE
1. Amor F, Alcazar JL, Vaccaro H, Leon M, Iturra A. GI-RADS reporting system for ultrasound evaluation of adnexal masses in clinical practice: a prospective multicenter study. Ultrasound Obstet Gynecol
More informationProteomics-based Testing for the Evaluation of Ovarian (Adnexal) Masses
MP 2.04.50 Proteomics-based Testing for the Evaluation of Ovarian (Adnexal) Masses Medical Policy Section Medicine Issue 12:2013 Subsection Original Policy Date 12:2013 Last Review Status/Date Reviewed
More informationPerformance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center
Ultrasound Obstet Gynecol 2017; 49: 778 783 Published online 12 April 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.15963 Performance of the IOTA ADNEX model in preoperative discrimination
More informationExternal validation of IOTA simple descriptors and simple rules for classifying adnexal masses
Ultrasound Obstet Gynecol 2016; 48: 397 402 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.15854 External validation of IOTA simple descriptors and simple rules for
More informationIs CA-125 the Leading Biomarker in Determining Early-Onset Ovarian Cancer Diagnosis in 2016?
University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2016 Is CA-125 the Leading Biomarker in Determining Early-Onset Ovarian Cancer Diagnosis
More informationPerformance of the Risk of Malignancy Index for Discriminating Malignant Tumors in Women With Adnexal Masses
ORIGINAL RESEARCH Performance of the Risk of Malignancy Index for Discriminating Malignant Tumors in Women With Adnexal Masses Camila Campos, MD, Luis Otávio Sarian, MD, PhD, Rodrigo Menezes Jales, MD,
More informationA comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
DOI:10.6061/clinics/2012(05)06 CLINICAL SCIENCE A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses Cristina Anton,
More informationDiagnostic accuracy of ultrasonography with color doppler imaging techniques in adnexal masses and correlation with histopathological analysis
Original Article Diagnostic accuracy of ultrasonography with color doppler imaging techniques in adnexal masses and correlation with histopathological analysis Neha Gupta 1*, Poonam Gupta 2, Omvati Gupta
More informationOvarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT)
Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT) ACOG District II 2 Learning Objectives At the end of this clinical presentation, obstetrician gynecologists and other women s health care
More informationOriginal Article Risk of Malignancy Index (Adnexal Masses) Pak Armed Forces Med J 2014; 64 (4): Qurratulain Mushtaq, Mona Zafar, Sarwat Navid
Original Article Risk of Malignancy Index (Adnexal Masses) Pak Armed Forces Med J 2014; 64 (4):528-32 ACCURACY OF RISK OF MALIGNANCY INDEX IN PREOPERATIVE EVALUATION OF ADNEXAL MASSES Qurratulain Mushtaq,
More informationCharacterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010
Characterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010 Evan S. Siegelman MD University of Pennsylvania Medical Center Adnexal Masses: Pearls
More informationDSJUOG ABSTRACT INTRODUCTION. Materials AND METHODS /jp-journals
Leire Juez et al Original research 10.5005/jp-journals-10009-1398 Ultrasound Features for Determining the Risk of Malignancy in Unilocular-Solid Adnexal Masses in Premenopausal Women without Ascites and/or
More informationRadiological Reasoning: Imaging Characterization of Bilateral Adnexal Masses
AJR Integrative Imaging LIFELONG LEARNING FOR RADIOLOGY This Radiological Reasoning article is available for SAM credit and CME credits when completed with the additional educational material provided
More informationCarbohydrate antigen 125 or cancer
original article Oman Medical Journal [2015], Vol. 30, No. 6: 428 434 Validity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian Cancer Khawla Al-Musalhi 1 *,
More information